Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales ...

To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

Some might describe Johnson & Johnson's business as boring, but sometimes, that's not such a bad thing. Selling pharmaceutical products is a steady and reliable business even when the economy is ...

nor has Johnson & Johnson's stock market performance. Is the pharmaceutical giant still worth investing in? Some might describe Johnson & Johnson's business as boring, but sometimes, that's not ...

The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

It’s nearly a year and a half since Johnson & Johnson split off its consumer-health arm to focus on pharmaceuticals and medical technology. Johnson & Johnson has wasted no time expanding its ...

Budget 2025: Seeks to further amend notification No. 16/2017-Customs, dated the 20th April, 2017 so to exempt certain drugs for supply under Patient Assistance Programme run by specified ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

A collection of prominent healthcare interests were among the donors to President Donald Trump’s inaugural fund. | The pharma ...